Perceptive Advisors’s BioMarin Pharmaceuticals BMRN Stock Holding History

Perceptive Advisors’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-263,207	Closed	-$22.8M	–	99
2023 Q2	$22.8M	Sell	263,207 -409,853	-61%	-$38.6M	0.66%	46
2023 Q1	$65.4M	Buy	673,060 +166,579	+33%	+$17.3M	1.93%	13
2022 Q4	$52.4M	Buy	506,481 +170,000	+51%	+$16M	1.47%	22
2022 Q3	$28.5M	Buy	336,481 +156,481	+87%	+$13.9M	0.83%	32
2022 Q2	$14.9M	Buy	+180,000	New	+$14.3M	0.47%	47
2022 Q1	–	Sell	-1,180,000	Closed	-$104M	–	140
2021 Q4	$104M	Buy	+1,180,000	New	+$97.4M	1.61%	17
2017 Q2	–	Sell	-250	Closed	-$22K	–	138
2017 Q1	$22K	Hold	250	–	–	﹤0.01%	143
2016 Q4	$21K	Hold	250	–	–	﹤0.01%	158
2016 Q3	$23K	Buy	+250	New	+$23.5K	﹤0.01%	179

Other funds holding BMRN

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Perceptive Advisors's BMRN Position: Q3 2023 in Review

Perceptive Advisors sold out of BioMarin Pharmaceuticals (BMRN) in Q3 2023, closing a stake of 263,207 shares — an estimated $22.8M sold.

Perceptive Advisors first reported a position in BMRN in Q3 2016 and held it in 9 quarters. The position peaked at $104M in Q4 2021. 519 funds tracked by Wall St. Rank hold BMRN as of Q3 2023.

Perceptive Advisors reported no remaining BioMarin Pharmaceuticals position as of Q3 2023 after selling out during the quarter.
Perceptive Advisors sold 263,207 BioMarin Pharmaceuticals shares in Q3 2023, an estimated $22.8M.
Perceptive Advisors first reported a position in BioMarin Pharmaceuticals in Q3 2016 and held it in 9 quarters.
Perceptive Advisors's BioMarin Pharmaceuticals position peaked at $104M in Q4 2021.
519 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q3 2023.

Based on Perceptive Advisors's 13F filing for Q3 2023, filed 14 Nov 2023.